MedTrace Logo

Reward and Drug Effects on Mood and Brain Response

NCT04512365 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2025-05-21

No results posted yet for this study

Summary

The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.

Conditions

  • Cannabis Use
  • Healthy

Interventions

DRUG

Placebo oral capsule

A capsule that contains only dextrose filler administered during the first or second laboratory visit.

DRUG

THC

A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Natania A Crane, PhD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2025-05-02
Completion
2025-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512365 on ClinicalTrials.gov